News & Publications
Stanford Medicine News: Cancer
Cisplatin chemotherapy can bring lasting adverse health effects, but a new, presumably less-toxic alternative is not as effective at promoting survival, according to a large, Stanford-led trial.
An immunotherapy conceived at Stanford appeared safe in an early clinical trial. Half of the participants responded positively to the treatment, aimed at triggering macrophages to engulf cancer cells, the researchers reported.
Understanding when and where proteins bind to DNA may be the ticket to identifying cancer at the cellular level, according to researchers at Stanford.
A cancer biologist, Artandi studies the role of telomerase in stem cells and cancer. He replaces outgoing director Beverly Mitchell.
A quarterly publication for patients and friends of the Stanford Cancer Institute.
A publication with timely information for the cancer researchers, physicians and staff who make up the membership of the Stanford Cancer Institute.